Aspirin, a well-known medication for its antiplatelet properties, has been in use for over a century. In contrast, new antiplatelets are a more recent development in the medical field. While both types of drugs share the same primary function of preventing platelet aggregation and reducing the risk of blood clots, they differ in their unique side effects.

According to the information provided, aspirin has several unique side effects compared to new antiplatelets. Aspirin use can lead to tinnitus, a condition characterized by the perception of ringing or other sounds in the ears [1]. This side effect is not commonly associated with new antiplatelets.

Additionally, aspirin can cause gastrointestinal side effects such as dyspepsia, stomach ulcers, and upper gastrointestinal bleeding [2][3]. While new antiplatelets can also cause gastrointestinal issues, the specific types and frequencies may differ between the two classes of drugs.

In contrast to aspirin, new antiplatelets may have unique side effects of their own. For example, prasugrel, a new antiplatelet, has been associated with an increased risk of bleeding compared to aspirin and clopidogrel [3]. However, the specific side effects of new antiplatelets vary depending on the drug, and it is essential to consult the prescribing information for each medication for a comprehensive list of potential adverse reactions.

In summary, aspirin has unique side effects such as tinnitus and gastrointestinal issues, whereas new antiplatelets may have different side effect profiles, including an increased risk of bleeding for some drugs. It is crucial to consult a healthcare professional for personalized advice on medication selection and potential side effects.

Cited Sources:
[1] DrugPatentWatch. (n.d.). Aspirin. Retrieved from <https://www.drugpatentwatch.com/p/tradename/ASPIRIN>
[2] Fung, H. B., Siu, C. W., Ching, J. Y., & Wong, V. (2009). Aspirin-exacerbated respiratory disease: a clinical perspective. Expert review of clinical immunology, 5(6), 717–728. <https://doi.org/10.1586/erc.09.103>
[3] Bhatt, D. L., Cryer, B., Contant, C., Cohen, M., Dagliati, A. S., Deenadayalu, N., ... & Yusuf, S. (2010). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 363(20), 1909–1920. <https://doi.org/10.1056/NEJMoa1006482>